13 completed, 5 terminated, 4 active not recruiting, 3 recruiting. 13 Phase 2, 8 Phase 1, 8 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Ovarian Clear Cell Adenocarcinoma: new trials by email Literature Review of Ovarian Clear Cell Adenocarcinoma trials Research Report on Ovarian Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer NXP800 - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvectis Pharma, Inc. | 45 | 2021-12-31 | 2026-08-06 |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Paclitaxel, Ruxolitinib Phosphate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Completed | NRG Oncology | 147 | 2016-11-14 | 2025-05-25 |
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2016-09-01 | 2021-10-06 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biospecimen Collection, Carboplatin, Cediranib Maleate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 579 | 2016-03-28 | 2026-10-01 |
| Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 13 | 2015-04-01 | 2020-03-10 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 32 | 2012-03-09 | 2019-08-29 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
Showing 20 of 28. Sign in to see all of them.
Fallopian Tube Neoplasms (22) · Ovarian Neoplasms (22) · Brenner Tumor (12) · Carcinoma (3) · Endometrial Neoplasms (2) · Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Carcinoma, Ovarian Epithelial (1) · Mesothelioma, Malignant (1) · Triple Negative Breast Neoplasms (1)
Adnexal Diseases (27) · Female Urogenital Diseases (27) · Female Urogenital Diseases and Pregnancy Complications (27) · Genital Diseases (27) · Genital Diseases, Female (27) · Genital Neoplasms, Female (27) · Urogenital Diseases (27) · Urogenital Neoplasms (27) · Neoplasms by Site (26) · Endocrine System Diseases (25) · Gonadal Disorders (25) · Neoplasms (25) · Ovarian Diseases (25) · Endocrine Gland Neoplasms (22) · Fallopian Tube Diseases (22)
Paclitaxel (13) · Taxes (13) · Bevacizumab (11) · Disulfides (11) · Immunoglobulin G (11) · Carboplatin (8) · Doxorubicin (3) · Gemcitabine (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · liposomal doxorubicin (3) · olaparib (3) · pembrolizumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2)
National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · Roswell Park Cancer Institute (3) · GOG Foundation (2) · Gynecologic Oncology Group (1) · Imperial College London (1) · Multitude Therapeutics Inc. (1) · NRG Oncology (1) · Nuvectis Pharma, Inc. (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1)
United States (26) · South Korea (5) · Canada (4) · Japan (4) · United Kingdom (2) · Australia (1) · China (1) · Germany (1) · Italy (1) · Mexico (1) · Netherlands (1) · Puerto Rico (1)
Emese Zsiros (3) · Anil K. Sood, MD (1) · Anil Sood (1) · Bradley J Monk (1) · Catherine Shannon (1) · Charles N Landen (1) · David Alberts (1) · Don Dizon (1) · Evanthia Galanis, M.D. (1) · Evanthia Galanis, MD (1) · Jermaine Coward (1) · Joan L Walker (1) · John H Farley (1) · John K Chan (1) · Jonathan Krell (1)
PMID 37185961, PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 27394382, PMID 28341300, PMID 28438473, PMID 29550184, PMID 29921512, PMID 30309721, PMID 31002578, PMID 31216226, PMID 31708167, PMID 31722153, PMID 33211063, PMID 33610319, PMID 34986897, PMID 35144591, PMID 35170751, PMID 35290101, PMID 35382842, PMID 35759733, PMID 36252167, PMID 36608382, PMID 38776484, PMID 39361946, PMID 39570589, PMID 39638782
U10CA180868 (12), U10CA027469 (8), P30CA016672 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), R01CA267690 (1), R21CA215662 (1), U10CA101165 (1), U10CA180830 (1), UG1CA189867 (1)